Featuring an interview with Prof Giuseppe Curigliano, including the following topics:
- Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00)
- Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02)
- Selection and sequencing of treatment for patients with HR-positive, HER2-negative disease who experience progression on CDK4/6 inhibition (9:40)
- Current and future role of HER2-targeted therapy for HER2-low and HER2-ultralow mBC (19:46)
- Selection and sequencing of therapy for patients with metastatic triple-negative breast cancer (29:53)
- Emerging innovative interventions for the treatment of mBC (37:17)
CME information and select publications